Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thymoglobulin pretreatment with minimized immunosuppression in first liver transplantation
2009-010640-34Phase 2Terminated
- Sponsor
- AOU Policlinico di Modena
- Start
- May 2009
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of antithymocyte globulin, tacrolimus and everolimus in Hepatic transplant rejection (LTR) (2 arms), sponsored by AOU Policlinico di Modena. Primary endpoints: T-regulatory lymphocyte levels at 12 months, Rejection-free survival and 6 more. Started May 2009; status: terminated.
02
Drugs
antithymocyte globulintacrolimuseverolimus
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on 2009-010640-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010640-34.